Too many dummies who never heard of ITEK a week ago and are now spouting off cluelessly.
Takeover talk is premature -- ITEK added three big guns to the management team just in the past week. You think they signed up for a three-month gig. ITEK needs to stay independent at least through the phase 3.
No need for a secondary, either. The FDA gave ITEK a golden ticket that skyrocketed the value of the international rights to traodenosen.
If you want to see an overpriced stock in the ophthalmic sector, it's not ITEK.
Look at EYEG -- what retina doc really wants to bring iontopheresis drug delivery (electric stimulation through the skin) into their clinic?
AERI also has a major competitor in the rho kinase category -- privately held Anakem.
The Anakem drug may be better than Rhopressa -- no hyperemia.
Do your homework.
Hey genius, ITEK can sell the international rights to their drug (plus milestone payments and future royalties) for about $200 million -- right now they can do this.
All you people yelling for a secondary are clueless about this industry.
International partner an easy deal now.
Probably the next big step for ITEK and the money will be significant.
(So don't count on a secondary to knock the stock down)
You can do a partnership at any time -- and ITEK is in a good position to do one now.
Of course you can't sell anything yet.
ITEK sold themselves cheap doing an IPO at 6 -- they had indicated they wanted to do it much higher.
Still a lot to like here.
I think ITEK can easily get a partner now for the international rights to the drug.
Maybe $150-$200 million from a partner and they won't need to sell more shares to fund the big tphase 3 trial.
I took a nice profit this am but will come back in on any dip to 7.50
Analysts comments should be very positive but the profit was too good to pass up.
Well, It''s nice to hear that we have some reasonable posters on this board.
I had numerous contacts with PVA management for years and they went from open and candid to totally buttoned up. All I've been getting lately is "we've been through thick and thin and that's how this business works. We can manage through this."
I definitely don't like the recent low-yield drilling results and I don''t think it's all because of tighter chokes. I think they may have drilled their best prospects first and what is left is generally mediocre.
I would agree with you except that PVA management has become tone deaf to their tough financial situation.
You have some big egos at the top of PVA.
I think their chance to make a good deal has passed them buy.
JimJones points out that the IPs on most of the recently filed wells are low because PVA is using tighter chokes to prolong production and create better economics when oil prices recover.
I have followed the PVA well filings for several years and I do see some tighter chokes now being used, but explain this one.
A Blonde Unit well filed Monday 7/13 in LaVaca County had an IP of 309 barrels of oil per day with a 26 choke. That just looks like a disappointing well with a normal PVA choke.
How much of this new PVA "strategy" is real and how much is a weak explanation for less productive acreage being drilled?
Maybe someone with industry experience can explain this one.